囊泡单胺转运体2抑制剂戊苯那嗪的研究进展

Advances in vesicular monoamine transporter 2 inhibitor valbenazine

戊苯那嗪是一种新型、高选择性囊泡单胺转运体2抑制剂, 2017年4月被美国食品和药物管理局批准用于治疗成人迟发性运动障碍。在为期6周的短期治疗和持续48周的长期治疗临床试验中,戊苯那嗪均显示出对迟发性运动障碍良好的治疗效果,其常见的不良反应有嗜睡和头痛等。

Valbenazine,a novel and highly selective vesicular monoamine transporter 2(VMAT2)inhibitor,was approved by U.S.Food and Drug Administration for treating tardive dyskinesia in adults in April 2017.Clinical trials showed that valbenazine was effective in treating tardive dyskinesia both in 6-week short-term studies and 48-week long-term extension trials,and the common adverse reactions of valbenazine were somnolence,headache,and so on.